Tri-GalNAc(OAc)3 TFA is an intermediate in the synthesis of GalNAc-LYTAC with anticancer activity. GalNAc-LYTAC engages the asialoglycoprotein receptor (ASGPR) for targeted protein degradation. tri-GalNAc: triantenerrary N-acetylgalactosamine; LYTAC: Lysosome-Targeting Chimera.
Usually ships within 24 hours.